Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 3208  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
CORRESPONDENCE
Year : 2013  |  Volume : 58  |  Issue : 4  |  Page : 316-317
More robust evidence and safety checks are required before autologous serum therapy as treatment for chronic urticaria can be recommended


Department of Allergy and Immunology, Apollo Gleneagles Hospital, Kolkata, West Bengal, India

Date of Web Publication25-Jun-2013

Correspondence Address:
Sujoy Khan
Department of Allergy and Immunology, Apollo Gleneagles Hospital, Kolkata, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.113964

Rights and Permissions



How to cite this article:
Khan S. More robust evidence and safety checks are required before autologous serum therapy as treatment for chronic urticaria can be recommended. Indian J Dermatol 2013;58:316-7

How to cite this URL:
Khan S. More robust evidence and safety checks are required before autologous serum therapy as treatment for chronic urticaria can be recommended. Indian J Dermatol [serial online] 2013 [cited 2019 May 20];58:316-7. Available from: http://www.e-ijd.org/text.asp?2013/58/4/316/113964


Sir,

The report by Patil et al. on use of autologous serum therapy (AST) for patients with chronic autoimmune urticaria (CAU), defined by the positive autologous serum skin test, needs to be critically reviewed for several reasons. [1] The reported response rate of 45% (9 of 20 patients) after use of AST is not followed-up by specific response parameters such as urticaria activity score over a time period. The authors have not provided other patient specific parameters such as thyroid autoimmunity or anti-nuclear antibody, concomitant medication use such as antihistamines or immunosuppressants to justify the conclusion.

The report does not elaborate on the details of the blood collection and serum preparation techniques including whether the screening tests for infectious diseases (HbsAg, antibodies to HCV or HCV-nucleic acid test, HIV-I/II, syphilis) were carried out on these patients before serum preparation. Previous published data on this procedure involves sterile collection of either 100 ml or one unit (470 ml) blood. Clot retraction is then allowed for 2 h at 21΀C (room temperature), centrifuged for 15 min at 3000 g and supernatant serum removed in a laminar air flow hood. A third of the amount of whole blood collected is generally the yield of serum. The serum is then diluted with an equivalent amount of balanced salt solution and filter sterilized. Aliquots of serum are then stored and samples sent to exclude microbiological contamination before administration and used within 3 months. [2] The authors do not discuss why they decided to give nine once-weekly intramuscular injections of autologous serum, nor provide a workable hypothesis of how this might work in CAU. There was no data provided on how long the "remission" lasted in the nine patients in whom the AST was effective.

Although, it is widely recognized that there is a need for new and rational treatments for this difficult-to-treat chronic disorder, it does not merit a reason such as a "poor man's biological" therapy for using AST. High cost of therapy of effective biological such as anti-IgE monoclonal antibody (Omalizumab) [3] alone should not dictate on the use of such treatment options given the possible health and safety risks of use of autologous serum as "treatment" for patients. This is more so given our past knowledge of transmissible prion protein diseases, and perhaps also the reason why the British Committee of Standards in Hematology has adopted new guidelines for pre-deposit autologous blood donation. [4] Clinicians should try and find ways of sourcing the well-tested and effective biologic drug Omalizumab or conduct a well-designed rigorous clinical trial on AST to prevent serious medical disasters.

 
   References Top

1.Patil S, Sharma N, Godse K. Autologous serum therapy in chronic urticaria. Indian J Dermatol 2013;58:225-6.  Back to cited text no. 1
  Medknow Journal  
2.Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88:1467-74.  Back to cited text no. 2
    
3.Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35.  Back to cited text no. 3
    
4.British Committee for Standards in Haematology, Transfusion Task Force, Boulton FE, James V. Guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion. Transfus Med 2007;17:354-65.  Back to cited text no. 4
    



This article has been cited by
1 Authorsę reply
Patil, S., Sharma, N., Godse, K.
Indian Journal of Dermatology. 2013;
[Pubmed]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (339 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1438    
    Printed24    
    Emailed1    
    PDF Downloaded51    
    Comments [Add]    
    Cited by others 1    

Recommend this journal